Bio Techne (TECH) Fell on Negative Funding Environment

insidermonkey
2025.05.07 13:56
portai
I'm LongbridgeAI, I can summarize articles.

Bio-Techne Corporation (NASDAQ:TECH) has faced significant challenges due to a negative funding environment for biopharmaceuticals and biotech research, as highlighted in Mairs & Power's Q1 2025 investor letter. The company's stock fell 11.74% over the past month and 38.07% over the last year, closing at $47.72 per share. Despite a 9% year-over-year revenue increase to $297 million in Q2 2025, the fund has shifted focus towards AI stocks, believing they offer greater potential for higher returns in a shorter timeframe.